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Summary
Congenital insensitivity to pain with anhidrosis (CIPA)
is characterized by recurrent episodes of unexplained
fever, anhidrosis (inability to sweat), absence of reaction
to noxious stimuli, self-mutilating behavior, and mental
retardation. Human TRKA encodes a high-affinity ty-
rosine kinase receptor for nerve growth factor (NGF), a
member of the neurotrophin family that induces neurite
outgrowth and promotes survival of embryonic sensory
and sympathetic neurons. We have recently demon-
strated that TRKA is responsible for CIPA by identifying
three mutations in a region encoding the intracellular
tyrosine kinase domain of TRKA in one Ecuadorian and
three Japanese families. We have developed a compre-
hensive strategy to screen for TRKA mutations, on the
basis of the gene’s structure and organization. Here we
report 11 novel mutations, in seven affected families.
These are six missense mutations, two frameshift mu-
tations, one nonsense mutation, and two splice-site mu-
tations. Mendelian inheritance of the mutations is con-
firmed in six families for which parent samples are
available. Two mutations are linked, on the same chro-
mosome, to Arg85Ser and to His598Tyr;Gly607Val,
hence, they probably represent double and triple mu-
tations. The mutations are distributed in an extracellular
domain, involved in NGF binding, as well as the intra-
cellular signal-transduction domain. These data suggest
that TRKA defects cause CIPA in various ethnic groups.
Received January 8, 1999; accepted for publication April 6, 1999;
electronically published May 3, 1999.
Address for correspondence and reprints: Dr. Yasuhiro Indo, De-
partment of Pediatrics, Kumamoto University School of Medicine,
Honjo 1-1-1, Kumamoto 860-8556, Japan. E-mail: yindo@kaiju.medic
.kumamoto-u.ac.jp
 1999 by The American Society of Human Genetics. All rights reserved.
0002-9297/99/6406-0010$02.00
Introduction
Congenital insensitivity to pain with anhidrosis (CIPA;
MIM 256800) is a rare autosomal recessive disorder
characterized by recurrent episodes of unexplained fever,
anhidrosis (inability to sweat), absence of reaction to
noxious stimuli, self-mutilating behavior, and mental re-
tardation (Swanson 1963; Dyck 1984; McKusick 1994).
CIPA is also known as “congenital sensory neuropathy
with anhidrosis,” “hereditary sensory and autonomic
neuropathy type IV,” and “familial dysautonomia type
II.” In CIPA, there is a lack of pain sensation, most likely
the result of the absence of the dorsal root ganglia re-
sponsible for pain sensation. A feature of CIPA is the
absence of small-diameter afferent neurons, which are
activated by tissue-damaging stimuli (Swanson et al.
1965; Rafel et al. 1980). A loss of innervation of eccrine
sweat glands, by sympathetic neurons, explains the phe-
nomenon of anhidrosis (Langer et al. 1981; Ismail et al.
1998). Previously, the diagnosis of CIPA was established
on the basis of clinical findings, pharmacological tests,
and peripheral-nerve biopsy.
Nerve growth factor (NGF) is the first growth factor
to be identified and characterized (Levi-Montalcini
1987). Cell survival, growth, and differentiation in the
nervous system are mediated by numerous growth fac-
tors, including neurotrophic factors (neurotrophins).
NGF supports the survival of sympathetic ganglion neu-
rons and nociceptive sensory neurons in dorsal root gan-
glia, derived from the neural crest, and ascending cho-
linergic neurons of the basal forebrain (Levi-Montalcini
1987; Thoenen and Barde 1980). TRKA (also named
NTRK1) was isolated from a colon carcinoma as a po-
tential new member of the tyrosine kinase gene family
(Martin-Zanca et al. 1986) and was later found to be
expressed in the nervous system (Martin-Zanca et al.
1990). TRKA is a receptor tyrosine kinase that is phos-
phorylated in response to NGF (Kaplan et al. 1991;
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Klein et al. 1991). A single transmembrane domain di-
vides TRKA into an extracellular domain, important for
NGF binding, and an intracellular tyrosine kinase do-
main, important for signal transduction.
Mice lacking the orthologous gene of human TRKA
share dramatic phenotypic features of CIPA, including
loss of responses to painful stimuli, although anhidrosis
is not apparent in these animals (Smeyne et al. 1994;
Snider 1994). In addition, all dorsal root ganglia neurons
associated with nociceptive functions are lost in the de-
ficient mice. They also have extensive neural cell loss in
sympathetic ganglia and a decrease in cholinergic neu-
rons of the basal forebrain. We therefore considered hu-
man TRKA as a candidate gene for CIPA. We identified
the genetic basis for this disorder by showing that mu-
tations in TRKA are associated with the absence of func-
tional high-affinity NGF receptors in four patients (Indo
et al. 1996). We focused on the region encoding the
intracellular domain, since the whole structure of human
TRKA was not known. CIPA is the first human genetic
disorder implicated in the neurotrophin-signal–trans-
duction system. The anomalous pain and temperature
sensation in CIPA is probably because of a dramatic loss
of unmyelinated C-fibers and small-diameter myelinated
A-fibers in the afferent neurons. The NGF-TRKA system
has a crucial role in the development and function of
nociception, as well as the establishment of thermoreg-
ulation via sweating in humans.
Human TRKA maps to chromosome 1q (Miozzo et
al. 1990; Morris et al. 1991). Recently, we and others
independently determined the structure and organization
of human TRKA (Greco et al. 1996; Indo et al. 1997;
GenBank). We have established a method to amplify and
analyze all coding exons from genomic DNA. This study
describes the analysis of TRKA mutations in seven fam-
ilies from various ethnic groups, including nine CIPA
patients, by direct sequencing of all exons and reports
the detection of 11 novel mutations. The mutations re-
sponsible for CIPA are distributed in the extracellular
domain, important for NGF binding, as well as in the
intracellular domain, important for signal transduction.
These data suggest that TRKA mutations cause CIPA in
various ethnic groups and give insight into the structure
and function relationship of the neurotrophin receptor
tyrosine kinase family.
Patients and Methods
Patients
Seven affected families, including nine patients with
CIPA, were studied: two each from Kuwait (KI-103 and
KI-105) and Italy (KI-106 and KI-107); and one each
from United Arab Emirates (KI-102), Spain (KI-104),
and Canada (KI-108). All patients had characteristic fea-
tures of CIPA, insensitivity to pain and anhidrosis. Lack
of eccrine sweat-gland innervation was confirmed in the
KI-103 patient (Ismail et al. 1998). Parents were con-
sanguineous in families KI-102, -103, -104, -105, and
-106. Affected individuals were diagnosed with CIPA on
the basis of clinical findings or by pharmacological and
pathological analyses. We also studied parents (obligate
carriers) and sibling(s) in all families, except one. DNA
samples of parents from family KI-107 were not avail-
able for testing. At least 50 unaffected Japanese indi-
viduals were screened to verify that the mutations found
in patients with CIPA were absent in the normal pop-
ulation. DNA samples for all patients with CIPA, their
family members, and normal individuals were obtained
from peripheral blood leukocytes by standard methods.
Blood was collected from patients with CIPA and family
members, who were referred to the investigators, after
giving informed consent.
PCR Amplification of TRKA Exons and Sequencing
TRKA exons were amplified from genomic DNA by
use of specific primers, derived from the 5′ and 3′ intronic
or exonic sequences (table 1), and AmpliTaq (PE Applied
Biosystems) or Expand Long Template PCR (Boehringer-
Mannheim). The annealing temperature for each pair of
primers was 54C–62C. A microsatellite (D1S506) is
located in intron 12. Two or three consecutive exons
(i.e., 2 and 3; 5 and 6; 9, 10, and 11; and 13 and 14)
were amplified simultaneously. The corresponding PCR
products were purified by Microcon 100 (Millipore) or
by agarose gel electrophoresis and QIAEX II Gel Ex-
traction kit (QIAGEN). Direct sequencing of PCR prod-
ucts was performed with dRhodamine Terminator Cycle
Sequencing Kit (PE Applied Biosystems). Sequences were
resolved and analyzed on an ABI PRISM 310 Genetic
Analyzer (PE Applied Biosystems). Amplified segments
were sequenced directly or were subcloned into the T-
vector, in the case of a compound heterozygote in which
there were two different mutations. The plasmid vector,
pBluescript KS() (Stratagene), was digested with
EcoRV and treated with Taq polymerase (Marchuk et
al. 1991). Sequence was determined as described above.
Detected mutations were described according to a no-
menclature system for human gene mutations (Anton-
arakis 1998).
Restriction-Digestion Analysis
For analysis of family KI-102, genomic DNA was am-
plified with a set of primers, gTRKA(56)F and TRKA-
L600. PCR products were digested with MvaI and elec-
trophoresed. Conditions for PCR are described above.
For analysis of family KI-104, PCR products, amplified
with a set of primers for exon 15, were digested with
MspI. The products were incubated with each restriction
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Table 1
Primer Sequence Used for the TRKA Gene
ANALYSIS AND PRIMER NAME Exons
PRIMER SEQUENCE (5′r3′)
PCR
Product
(bp)Forward Reverse
PCR direct sequence:
gTRKA(1)F/R 1 AGCTGGGAGCGCACAGACGG CAGCAAACAAGCAGCGAGTC 323
gTRKA(23)F/R 23 TGTGACTCCCATCCGCTCTC TGTCCTCCCCAACTCCCACT 516
gTRKA(4)F/R 4 GCTCCTCCCCTCCCTCATTC GTCATCCAACAGACCCAAGT 224
gTRKA(56)F/R 56 CTCCCTCTTATCCCCTGTGA CTTTGTCCCCTGTGCTCTGC 716
gTRKA(7)F/R 7 CCTCCTCTCCTTTCCATCTG CACCCTACATCCTCTTTTGA 312
gTRKA(8)F/R 8 TTCGGGTTCTACTCGCTTTG TGGGGGCAGGGTTCAGGATG 456
gTRKA(91011)F/R 91011 CCAGCAGCCCACCTCCATCC TACCCCAAACACACTCACAC 895
gTRKA(12)F/R 12 AGTTACAAGGTGGGGGTGAC GGGCCTATGGCTGGAA 388a
gTRKA(1314)F/R 1314 CAACCCCAGCCCTCCCAAGA CTATGTTCACACATCTGCCT 724
gTRKA(15)F/R 15 CCAGTCTCCTCTCCCATCAC TGGGATCCAGGGTGTCTACA 406
gTRKA(16)F/R 16 TAATGATGGGGCTGGGGTAG AGGCCAGCAAGGGGTGACCA 276
gTRKA(17)F/R 17 GCTTTCTCCTCTGTCTCTCC ATTCCGGCTAACCACTCCCA 254
Restriction enzyme:
gTRKA(56)F/TRKA-L600 5 (partial) CTCCCTCTTATCCCCTGTGA CATGACACTGCAGCTTCTGT 176
Exon trap:
gTRKA(4)F/gTRKA(5)R 45 GCTCCTCCCCTCCCTCATTC TTTCAGTGCTTGCTCAGTGCC ∼1,400
gTRKA(7)F/gTRKA(8)R 78 CCTCCTCTCCTTTCCATCTG TGGGGGCAGGGTTCAGGATG ∼2,600
SD6/TRKA-L600 5 (partial) ATTTAGGTGACACTATAG CATGACACTGCAGCTTCTGT 268
TRKA-U842/TRKA-L1144 78 (partial) ATGTCACCAGTGACCTCAAC GTGTAGTTGCCGTTGTTGAC 323
a Number in which gt repeats of microsatellite D1S506  20.
enzyme and electrophoresed onto a 4% NuSieve agarose
gel (FMC BioProducts).
Exon Trapping System
An Exon Trapping System (Gibco BRL) was used to
confirm putative splice-site mutations in vitro, according
to the manufacturer’s protocol. For a mutation on the
splice-acceptor site of intron 4, a 1.4-kb fragment, con-
taining exons 4 and 5, was amplified with a set of prim-
ers—forward, gTRKA(4)F and reverse, gTRKA(5)R—
each from the patient or control. For a mutation on the
splice-donor site of intron 7, a 2.6-kb fragment, con-
taining exons 7 and 8, was amplified with a set of prim-
ers—forward, gTRKA(7)F and reverse, gTRKA(8)R—
each from the patient or control. Amplified products
were cloned into the T-vector and sequenced as described
above. Subsequently, a XhoI-BamI fragment, containing
the insert from each clone, was subcloned into an exon
trapping vector, pSPL3 (Gibco BRL). The pSPL3 deriv-
atives were propagated in Escherichia coli, and the DNA
was then isolated and transfected into COS-1 cells by
Lipofectamin (Gibco BRL). The following day, cells were
harvested and RNA isolated. To characterize a DNA
segment trapped as an exon, mRNAs were amplified by
RT-PCR, by use of random hexamer (for reverse tran-
scription) and a set of primers, to locate corresponding
exons of TRKA. Primer set SD6, in the pSPL3-vector
sequence, and TRKA-L600, in exon 5, were used for
detection of exon 5, whereas primer set TRKA-U842,
in exon 7, and TRKA-L1144, in exon 8, were used for
detection of exon 7. We also performed RT-PCR analysis
of the E2 gene of the branched-chain a-keto-
acid–dehydrogenase complex, as a positive control, to
demonstrate the integrity of the mRNA and reverse tran-
scription. A set of primers, E2-4/E2-7, for E2, was de-
scribed elsewhere (Tsuruta et al. 1998).
Results
Physical Characteristics of a Patient with CIPA
We present a patient, to describe the physical char-
acteristics associated with this disorder (fig. 1). The pa-
tient is a 5-year-old white girl of mixed Czech and Eng-
lish-German ancestry, born to nonconsanguineous
parents. There are no abnormalities of the hair, eye-
brows, or eyelashes (fig. 1A). She presents with recurrent
unexplained fevers and anhidrosis by history. She de-
veloped palmoplantar hyperkeratosis, with significant
fissuring of the plantar skin (fig. 1B, C). Since a very
young age, she has demonstrated self-mutilating behav-
ior (avulsion of teeth, biting of distal extremities), and
she has had several deep heel ulcers that take a long time
to heal, yet are painless (fig. 1C). The mutations in this
patient are described below (family KI-108).
Mutations in TRKA in CIPA Families
Seven unrelated CIPA families were screened for mu-
tations in the TRKA gene. These include nine patients,
four normal siblings, and 12 obligate carriers. All 17
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Figure 1 Physical characteristics of a patient with CIPA, a 5-
year-old white girl born to nonconsanguineous parents. A,There are
no abnormalities of the hair, eyebrows, or eyelashes. B, Palmar skin
is dry and hyperkeratotic. C, Plantar skin is dry and hyperkeratotic,
with significant fissuring. Deep heel ulcers are painless and slow to
heal. Informed consent for publication of photographs was obtained
from her parents.
exons of the TRKA gene, including their flanking in-
tronic sequences, were amplified from the genomic DNA
of each patient with CIPA by use of the PCR primers
specified in table 1. All exons and intron-exon bound-
aries were sequenced. We detected putative mutation(s)
in the proband. For missense mutations, we compared
DNA sequences from 100 nonaffected chromosomes to
reduce the likelihood that the described change repre-
sented a polymorphism.
In a male patient with CIPA, of family KI-102, se-
quencing of genomic DNA revealed that a 3′ splice site
contained a GrC transversion in the first position of
intron 4 (IVS41GrC; fig. 2A and table 2). The sub-
stitution destroys a restriction enzyme site for MvaI. Di-
gestion analysis with this enzyme also demonstrated that
the proband and parents were homozygous and hetero-
zygous, respectively (fig. 2A). In addition, we detected
a CrA transversion at nucleotide 337 in exon 2, which
causes an ArgrSer substitution at amino acid 85
(Arg85Ser; table 2). Both parents were heterozygous for
this substitution (data not shown).
In family KI-103 a single base A at nucleotide 284
was deleted, in exon 1 of the two female patients (fig.
2B and table 2). The deletion (∼284delA) causes a frame-
shift and premature termination codon after amino acid
Asn 67 (Asn67fr). The patients and parents were ho-
mozygous and heterozygous, respectively. One of three
male siblings with normal phenotype was wild type, and
the other two were heterozygous for this deletion. Thus,
∼284delA is apparently the cause of CIPA in this family.
In family KI-104 we found a CrT transition, at nu-
cleotide 2011 in exon 15 (∼2011CrT), which causes an
ArgrTrp substitution at amino acid 643 (Arg643Trp)
(fig. 2C and table 2). After amplification of exon 15 from
parental genomic DNA, we detected mutant and wild-
type alleles. The substitution destroys a restriction-en-
zyme site for MspI. Digestion analysis with this enzyme
showed that the patient and parents were homozygous
and heterozygous, respectively (fig. 2C).
In two female patients with CIPA, from family KI-
105, a 5′ splice site of intron 7 contained a GrA sub-
stitution in the first position (IVS71GrA) (fig. 2D and
table 2). The proband and parents were homozygous
and heterozygous for IVS71GrA, respectively. A fe-
male sibling with normal phenotype was heterozygous.
In family KI-106 we found a CrT transition at nu-
cleotide 109 (109CrT) in exon 1, which changes a Gln
to a termination codon at amino acid 9 (Gln9X) in the
proband (fig. 2E [upper] and table 2). In addition, we
detected two further base changes, both in exon 15: a
CrT transition at nucleotide 1876 (∼1876CrT) and a
GrT transversion at nucleotide 1904 (∼1904GrT) that
cause a HisrTyr substitution at amino acid 598
(His598Tyr) and a GlyrVal substitution at amino acid
607 (Gly607Val), respectively (data not shown). The
Figure 2 Mutation analysis of human TRKA, in seven CIPA families. A, In family KI-02 a GrC transversion at the first position of the
3′ splice site in intron 4 (IVS41GrC) (upper) and restriction-digestion analysis with MvaI (lower) are shown. Shown are a normal control
(lane 1), the patient (lane 2), and the patient’s father and mother (lanes 3 and 4). B, A single base deletion at nucleotide 284 of exon 1, in
family KI-103. Reverse sequences are shown. Shown are a normal control (box 1); the proband, as a representative patient in this family (box
2); and the father, as a representative heterozygote (box 3). The proband and her younger sister with CIPA are homozygous for the mutation.
An older brother is normal. Two younger brothers with normal phenotype and both parents are heterozygous. C, In family KI-104 a CrT
transition at nucleotide 2011 in exon 15 (upper) and restriction-digestion analysis with MspI (lower) are shown. The transition causes an
ArgrTrp substitution at amino acid 643. Shown are a normal control (lane 1); the patient (lane 2); and the patient’s father and mother (lanes
3 and 4). D, A GrA transition at the first position of the 5′ splice site in intron 7, in family KI-105. Shown are a normal control (box 1); the
proband, as a representative patient in this family (box 2); and the father, as a representative heterozygote (box 3). The proband and her
younger sister with CIPA are homozygous for the mutation. Both parents and her younger sister with normal phenotype are heterozygous. E,
In family KI-106, a CrT transition at nucleotide 109 in exon 1 causes a Gln codon to become a termination codon at position 9, as shown
in the upper part. Shown are a normal control (box 1), the patient (box 2), and the patient’s father and mother (boxes 3 and 4). In family KI-
107, a GrA transition at nucleotide 2206 in exon 16 causes a GlyrSer substitution at amino acid 708, as shown in the lower part. DNA
samples from parents were not available for testing in this family. F, Two different mutations at the TRKA locus, in family KI-108. A 7-bp
deletion, from nucleotide 1008 to 1014 in exon 8 (∼1008–1014delGCCGGCA), causes a frameshift after amino acid Gln308 and premature
termination codon downstream, as shown for control and subcloned mutant sequences, respectively (boxes 1 and 2). This mutation is derived
from her father (box 3). The other, a TrC transition at nucleotide 722 in exon 6, causes a LeurPro substitution at amino acid 213; results of
the PCR direct sequence are shown in reverse orientation for control and mutant sequences, respectively (boxes 4 and 5). The latter mutation
is derived from her mother (box 6).
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Table 2
Mutation Analysis of CIPA Families
Family Consanguinity Status Nucleotide Change (Location)
Mutation Type
(Predicted
Consequence)
Country
of Origin
KI-102 Yes Homozygote IVS41GrC; ∼337CrA (intron 4;
exon 2)
Splice site; missense (aberrant splicing
of exon 5; Arg85Ser)
UAE
KI-103 Yes Homozygote ∼284delA (exon 1) Frameshift (truncation after Asn67) Kuwait
KI-104 Yes Homozygote ∼2011CrT (exon 15) Missense (Arg643Trp) Spain
KI-105 Yes Homozygote IVS71GrA (intron 7) Splice site (aberrant splicing of exon 7) Kuwait
KI-106 Yes Homozygote ∼109CrT; ∼1876CrT; ∼1904GrT
(exon 1; exon 15 ; exon 15)
Nonsense; missense; missense (Gln9X;
His598Tyr; Gly607Val)
Italy
KI-107 No Homozygote ∼2206GrA (exon 16) Missense (Gly708Ser) Italy
KI-108 No Compound
heterozy-
gote
∼722TrC (exon 6);
c.1008^1014delGCCGGCA (exon 8)
Missense (Leu213Pro);
frameshift (truncation after Gln308)
Canadaa
NOTE.—Positions of nucleotide change are from the transcription start site, as described by Martin-Zanca et al. (1989). The ATG initiation
codon is located at nucleotide position c85. The structure and organization of human TRKA were described by Indo et al. (1997).
a Family from Canada is of mixed Czech and English-German ancestry.
proband and both parents were homozygous and het-
erozygous for all base substitutions, respectively.
In family KI-107 a homozygous GrA transition at
nucleotide 2206 (∼2206GrA), in exon 16, was pre-
dicted to cause a GlyrSer substitution at amino acid
708 (Gly708Ser) (fig. 2E [lower] and table 2). DNA
samples from parents were not available for testing.
In family KI-108 the proband was a compound het-
erozygote, having two different mutations at the TRKA
locus on separate chromosomes (fig. 2F and table 2).
Each mutant allele was subcloned into a plasmid vector
and sequenced. One contained a 7-bp deletion, from
nucleotide 1008 to 1014 (∼1008–1014delGCCGGCA)
in exon 8, which is predicted to cause a frameshift after
amino acid Gln308 and create of a downstream pre-
mature termination codon (Gn308fr). The other was a
TrC transition at nucleotide 722 (∼722TrC) in exon
6, which causes a LeurPro substitution at amino acid
213 (Leu213Pro). Sequence analysis of the parents re-
vealed that (∼1008–1014delGCCGGCA) and
(∼722TrC)
were derived from the father and mother, respectively.
Exon Trap Analysis of Splice-Site Mutations
We characterized the IVS41GrC mutation in family
KI-102 and the IVS71GrA mutation in family KI-05
by using exon trap analysis, since mRNA preparations
from the patients were not available for testing. A 1.4-
kb fragment containing exons 4 and 5, or a 2.6-kb frag-
ment containing exons 7 and 8, as well as part of the
flanking introns, was amplified from proband and con-
trol samples. Each was subcloned into the exon trap
vector, pSPL3, to prepare a minigene construct. After
transfection of the minigene and incubation of cells, we
observed whether exon 5 or exon 7 was incorporated
into a transcript. RT-PCR analysis demonstrated that the
corresponding exon was incorporated in the control but
not in the patient (fig. 3A, B). A faint, large DNA frag-
ment was observed in the patient sample from family
KI-02 (fig. 3A). Sequence analysis of the fragment
showed that it was derived from an alternative splicing
event, which occurred at a cryptic splice-acceptor site in
intron 4 (IVS4-41; data not shown).
Thus, 11 novel mutations have been detected in seven
CIPA families from five countries. None of these mu-
tations were detected in 100 chromosomes from unre-
lated controls. Further, all appear to be “private muta-
tions,” restricted to each individual family.
Discussion
We reported elsewhere that TRKA is responsible for
CIPA (Indo et al. 1996). Given the lack of information
on the structure of the entire human TRKA gene, we
restricted our analysis to the region encoding the intra-
cellular tyrosine kinase domain. We detected three mu-
tations, R548fs, G571R, and IVS153ArC, in three
consanguineous Japanese CIPA families and in one con-
sanguineous Ecuadorian CIPA family. These mutations
are located in exon 14 and intron 15 (fig. 4). It has not
been confirmed whether all patients with CIPA have mu-
tation(s) in TRKA or whether there is genetic hetero-
geneity among various ethnic groups. Complete analysis
of patients with CIPA was hampered by the lack of a
full-length gene sequence; hence we report on the struc-
ture and organization of the whole human TRKA, to
facilitate mutation analysis (Indo et al. 1997).
Human TRKA is divided into 17 exons and 16 in-
trons. The entire sequence was estimated to span 23
kb, coding for a protein of 790 or 796 amino acid res-
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Figure 3 Exon-trap analysis of splice-site mutations in TRKA.
A, Characterization of the IVS41GrC mutation detected in family
KI-102. A fragment containing exons 4 and 5, as well as parts of
flanking introns, was subcloned into the exon trap vector, pSPL3, and
transfected into COS-1 cells. RT-PCR analysis was done on the mRNA
from such cells transfected with each vector construct. Shown are a
vector alone (lane 1), a vector with a normal TRKA gene (lane 2), a
vector with a mutant TRKA gene (lane 3), and PCR reaction without
a product by reverse transcription (lane 4). Exon 5 is incorporated in
the control but not in the patient. A 268-bp fragment was amplified
from the normal construct (lane 2). Faint bands in lane 3 are products
of alternative splicing, as described in the text. A housekeeping gene
was analyzed, as a control for integrity of the mRNA and of the RT-
PCR reaction. B, Characterization of the IVS71GrA mutation in
family KI-05. A fragment containing exons 7 and 8, as well as parts
of flanking introns, was used in a similar way, as described above.
Exon 7 is incorporated in the control but not in the patient. A 323-
bp fragment was amplified from the normal construct (lane 3).
idues. A single transmembrane domain divides the
TRKA protein into an extracellular and an intracellular
domain (Schneider and Schweiger 1991; Barbacid 1995;
Bothwell 1995). The extracellular domain is important
for specific NGF binding and includes a signal peptide;
three tandem leucine-rich motifs, flanked by two cysteine
clusters; and two immunoglobulin-like domains (or mo-
tifs). The intracellular domain includes a juxtamembrane
region, a tyrosine kinase domain, and a very short car-
boxyl-terminal tail. There is a general correlation be-
tween the genomic organization of TRKA and the func-
tional organization of the TRKA protein product (fig.
4) (Indo et al. 1997). Exon 1 contains the signal peptide
and the first cysteine cluster. Three leucine-rich motifs
are encoded by exons 2, 3, and 4. Exon 5 contains the
second cysteine cluster. The first immunoglobulin-like
motif is encoded by exons 6 and 7, whereas the second
immunoglobulin-like motif is encoded by the single exon
8. Thus, the splice sites of TRKA, encoding the extra-
cellular domain, separate the functional domains, so that
each is encoded by separate exons. Exon 9 is small (18
bp) and incorporated into mRNA by alternative splicing.
Six amino acid residues encoded by this exon are present
in the extracellular domain of the neuronal-specific
TRKA receptor (Barker et al. 1993). The transmembrane
domain is encoded by exons 10 and 11, and the intra-
cellular domain of TRKA is encoded by exons 11–17.
The juxtamembrane domain is encoded by exons 11 and
12. The domain contains an IXNPXpY motif, where “p”
indicates phosphorylation at the Tyr-490 residue of the
activated TRKA (Dikic et al. 1995). This motif is en-
coded by exon 12 and is recognized by an Shc-adapter
protein, required for activation of the Ras-MAPK path-
way (Obermeier et al. 1994; Stephens et al. 1994). The
tyrosine kinase domain that is phosphorylated in re-
sponse to NGF—and is critical for the intracellular sig-
naling—is encoded by exons 13–17. A consensus–
sequence motif YXXM, which interacts with phospha-
tidylinositol-3′ kinase, is located at the end of the kinase
catalytic domain (Tyr-751 residue in TRKA) (Obermeier
et al. 1993b; Soltoff et al. 1992) and encoded by exon
17. The short carboxyl-terminal tail of 15 amino acids
is also encoded by exon 17 and includes a conserved Tyr
residue (Tyr-785 in TRKA) that is responsible for bind-
ing of phospholipase Cg (Obermeier et al. 1993a; Loeb
et al. 1994).
In this report, we present the methodology to amplify
and analyze all coding exons from genomic DNA by
PCR direct sequencing. A total of 11 novel mutations
are described, in seven families from various ethnic
groups (fig. 4). CIPA mutations are spread throughout
the signal peptide, extracellular domain, and intracel-
lular domain. There are six missense mutations
(Arg85Ser, Leu213Pro, His598Tyr, Gly607Val,
Arg643Trp, and Gly708Ser), two frameshift mutations
(Asn67fs and Gln308fs), one nonsense mutation
(Gln9X), and two splice mutations (IVS41GrC and
IVS71GrA).
Three missense mutations, Leu213Pro, Arg643Trp,
and Gly708Ser, are probably responsible for CIPA. They
have not been observed in 100 normal chromosomes.
The Leu213Pro mutation is detected in a state of com-
pound heterozygosity in the patient who has a 7-bp de-
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Figure 4 Disease-associated mutations in TRKA. Amino acid numbering of the TRKA protein and structure of the TRKA gene are
according to Martin-Zanca et al. (1989) and Indo et al. (1997), respectively. Mutations reported in this study are listed above the TRKA
diagram, and three mutations, previously reported, are listed below the diagram. A nomenclature system for human gene mutations is used,
according to the recommendations of Antonarakis (1998). Mutations in brackets are detected as double or triple mutations, as described in
the text. Abbreviations listed in the lower part show the domain structures encoded by the corresponding exon(s) (Schneider and Schweiger
1991; Indo et al. 1997). SP  signal peptide; CC-1 and CC-2  the first and second cysteine clusters, respectively; LRMs  leucine-rich motifs;
Ig-1 and Ig-2  the first and second immunoglobulin-like motifs, respectively; TM  transmembrane; JX  juxtamembrane; and TK tyrosine
kinase.
letion on a separate chromosome. It is located in the
first immunoglobulin-like motif in the extracellular do-
main, which is important for NGF binding, and is con-
served between TRKA and TRKB. Both the Arg643Trp
and Gly708Ser mutations are located in the intracellular
tyrosine kinase domain and conserved among 14 re-
ceptor tyrosine kinases, including human TRKB and
TRKC (Martin-Zanca et al. 1989; Nakagawara et al.
1995). This suggests that they are important for enzyme
activity. Arg85Ser and (His598Tyr and Gly607Val) are
detected as a double and triple mutation, respectively,
and are described below. The His598Tyr mutation is
located in the intracellular tyrosine kinase domain and
conserved in three TRK families. However, Arg85Ser
(located in the leucine-rich motif of the extracellular do-
main) and Gly607Val (in the intracellular tyrosine kinase
domain) are not conserved. The effects of all these mis-
sense mutations on the function of the TRKA protein
are currently unknown, although experiments are in pro-
gress to address this question.
Two frameshift mutations, Asn67fs and Gln308fs, are
located in the first cysteine cluster and the second im-
munoglobulin-like motifs, respectively. These should re-
sult in truncation of the TRKA polypeptide in the ex-
tracelluar domain. Thus, these two mutations almost
certainly cause defects in NGF signal transduction.
The nonsense mutation, Gln9X, is located on the sig-
nal peptide and is associated with two missense muta-
tions (His598Tyr and Gly607Val) on the same chro-
mosome. The parents in this family are consanguineous,
and both are carriers of these three mutations. The pa-
tient is homozygous for all three. Thus, they probably
represent a triple mutation, although Gln9X is the most
likely cause of CIPA in this family. Triple mutation is
rare and has been reported in Gaucher disease (Hong et
al. 1990). In contrast, double mutations have been re-
ported in several clinically relevant genes, such as the
gene encoding the a-subunit of hexosaminidase A (Ains-
worth and Coulter-Mackie 1992), the low-density li-
poprotein receptor (Jensen et al. 1997), and so on. With-
out screening the entire coding region of TRKA in the
consanguineous homozygous patient, these CIPA mu-
tations would not have been detected. The triple mu-
tation awaits further study.
Two splice-site mutations (IVS41GrC and
IVS71CrA) cause skipping of exon 5 and exon 7,
respectively, in vitro. We predict that IVS41GrC and
IVS71GrA cause a skip of exon 5 or alternative splic-
ing, and a skip of exon 7, respectively, in vivo. These
exons are located in a region encoding the extracellular
domain of TRKA. These changes would result in a de-
letion of the second cysteine cluster or of a part of the
first immunoglobulin-like motifs. Further, these two
changes would result in a frameshift and cause a trun-
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cation of the TRKA protein. This structural change in
the extracellular domain would affect the function of
TRKA in NGF binding, and hence these splice mutations
are probably responsible for CIPA. In addition, the splice
IVS41GrC mutation is associated with Arg85Ser on
the same chromosome. The patient and both parents are
homozygous and heterozygous for these two substitu-
tions in this consanguineous family. Thus, these two
probably represent a double mutation. The
IVS41GrC is likely the main cause of CIPA in this
family, considering the effect of exon skipping or alter-
native splicing.
The data presented in this article represent the first
extensive mutation analysis of the whole TRKA gene in
CIPA patients from various ethnic groups. Mendelian
inheritance of the mutations was confirmed by sequence
analysis of the relevant amplified DNA fragment in fam-
ily members. These mutations do not seem to represent
frequent polymorphisms because they are not detected
in unaffected control individuals. We cannot completely
rule out the possibility that they are rare polymorphisms.
The three amino acid substitutions detected as double
or triple mutations might be rare polymorphisms in a
particular ethnic background.
Mutations responsible for CIPA are located in the ex-
tracellular domain as well as in the intracellular domain
of TRKA.They provide insight into the structure and
function, for neurotrophin members, of the TRK recep-
tor family. We did not observe any genotype-phenotype
correlation in the patients with CIPA we analyzed in this
study. All patients have typical features: insensitivity to
pain and anhidrosis. There seems to be no genetic het-
erogeneity in CIPA, although we cannot rule out the
possibility that mutation(s) in other gene(s) are respon-
sible for clinical phenotypes similar to CIPA.
CIPA is a painless but severe genetic disorder asso-
ciated with devastating complications, often leading to
crippling or fatal consequences. This study will facilitate
analyses of CIPA mutations in TRKA and provide an
invaluable aid for the diagnosis of this disorder and for
genetic counseling.
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